SOLIGENIX, INC. Finance Lease, Right-of-Use Asset, after Accumulated Amortization
SOLIGENIX, INC. (SNGX) had Finance Lease, Right-of-Use Asset, after Accumulated Amortization of $0 as of 2021-12-31, per its 10-K filed 2022-03-29.
Discontinued › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:FinanceLeaseRightOfUseAsset · last filed 2022-03-29
- 2021-12-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $0.00.
- 2021-09-30: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $0.00.
- 2021-06-30: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $1.86K.
- 2021-03-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $3.72K.
| Period end | Finance Lease, Right-of-Use Asset, after Accumulated Amortization |
|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-03-29 |
| 2021-09-30 | $0.00 10-Q · filed 2021-11-12 |
| 2021-06-30 | $1.86K 10-Q · filed 2021-08-13 |
| 2021-03-31 | $3.72K 10-Q · filed 2021-05-18 |
| 2020-12-31 | $5.58K 10-K · filed 2022-03-29 |
| 2019-12-31 | $13.03K 10-K · filed 2022-03-29 |
| 2019-09-30 | $14.89K 10-Q · filed 2019-11-12 |
| 2019-06-30 | $16.75K 10-Q · filed 2019-08-13 |
| 2019-03-31 | $18.61K 10-Q · filed 2019-05-14 |
| 2018-12-31 | $20.47K 10-K · filed 2021-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |